Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907346" target="_blank" >RIV/00216208:11120/13:43907346 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/13:#0000317 RIV/00064173:_____/13:N0000002
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1300815" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1300815</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1300815" target="_blank" >10.1056/NEJMoa1300815</a>
Alternative languages
Result language
angličtina
Original language name
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
Original language description
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant of PCI-related ischemic complications. Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects. METHODS In a double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI and were receiving guideline-recommended therapy to receive a bolus and infusion of cangrelor or to receive a loading dose of 600 mg or 300 mg of clopidogrel. The primary efficacy end point was a composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization; the key secondary end point was stent thrombosis at 48 hours. The primary safety end point was severe bleeding at 48 hours. RESULTS The rate of the primary efficacy end point was 4.7% in the cangrelor group and 5.9% in the clopidogrel group (ad
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
368
Issue of the periodical within the volume
14
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1303-1313
UT code for WoS article
000316989900007
EID of the result in the Scopus database
—